Literature DB >> 26441062

Joint involvement secondary to Epstein-Barr virus.

Carlos Manuel Feced Olmos1, Meritxell Fernández Matilla2, Montserrat Robustillo Villarino3, Isabel de la Morena Barrio3, Juan José Alegre Sancho3.   

Abstract

We describe a group of patients with Epstein-Barr virus (EBV) infection and joint involvement. Between February 2011 and January 2012, there were six cases in our unit. Two presented with a pattern similar to rheumatoid arthritis, three had polyarthralgia with an inflammatory pattern and only one patient had asymmetrical oligoarthritis of large joints. They were all women aged between 25 and 75 (4 were of child-bearing potential). Diagnosis in all the cases was made by exclusion of other possible causes and negative IgM were obtained for the rest of the "Herpesviridae" family viruses. In our series, EBV joint involvement was more common in women of childbearing potential. Clinical presentation was heterogeneous but was predominantly in the form of inflammatory joint pain. When it presents in the form of symmetrical polyarthritis, it can become chronic and require the use of disease-modifying anti-rheumatic drugs.
Copyright © 2015 Elsevier España, S.L.U. y Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved.

Entities:  

Keywords:  Arthritis; Artritis; Epstein Barr virus; Virus de Epstein Barr

Mesh:

Year:  2015        PMID: 26441062     DOI: 10.1016/j.reuma.2015.05.014

Source DB:  PubMed          Journal:  Reumatol Clin        ISSN: 1699-258X


  2 in total

1.  Effects of Chronic Diurnal Disruption and Acute Inflammatory Challenge on Mice with Latent Murine Gammaherpesvirus Infection.

Authors:  Rita A Trammell; Linda A Toth
Journal:  Comp Med       Date:  2016-12-01       Impact factor: 0.982

2.  Severe acute onset dry eye following presumed Epstein.Barr viral infection.

Authors:  Sumana Chatterjee; Geetha Iyer; Bhaskar Srinivasan; Shweta Agarwal; Jayanta Kuila
Journal:  Indian J Ophthalmol       Date:  2020-04       Impact factor: 1.848

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.